Eolo is developing an innovative weight-loss pill that emerged from research originally focused on tackling inflammation linked to obesity. Their experimental drug, shown to reduce body weight in mice on high-fat diets while preserving lean muscle mass, represents a significant advancement in anti-obesity treatment. The high costs and side effects associated with current GLP-1 injectable drugs have opened the market for oral alternatives. CEO María Pía Garat emphasizes the unmet clinical need, highlighting the potential for Eolo's drug to positively impact patients' treatment options.
Eolo's research initially aimed at reducing inflammation in obesity but unexpectedly led to a promising weight-loss effect without muscle mass loss in mice.
Drug companies are keen to develop oral anti-obesity medications, responding to high costs of injectables and patient preference for pills.
"There's still an unmet clinical need, and that's where Eolo wants to help," says María Pía Garat, signaling their commitment to innovate in weight-loss solutions.
Eolo's experimental drug not only decreased body weight in mice on a high-fat diet but also maintained lean body mass as confirmed by MRI scans.
Collection
[
|
...
]